Skip to main content

Author: Customer Service

Hesai Group to Report Third Quarter 2026 Financial Results on Tuesday, November 10, 2026

– Earnings Call Scheduled for 7:00 AM ET on November 10, 2026 – SHANGHAI, China, Oct. 20, 2026 (GLOBE NEWSWIRE) — Hesai Group (Nasdaq: HSAI; HKEX: 2525) (“Hesai” or the “Company”), a Physical AI infrastructure company, today announced that it will report its third quarter 2026 unaudited financial results on Tuesday, November 10, 2026, before the U.S. market opens. The Company’s management will host an earnings conference call at 7:00 AM U.S. Eastern Time on November 10, 2026 (8:00 PM Beijing/Hong Kong Time on November 10, 2026). For participants who wish to join the call by phone, please access the link provided below to complete the pre-registration and dial in 5 minutes prior to the scheduled call start time. Upon registration, each participant will receive dial-in details to join the conference call.Event Title: Hesai...

Continue reading

Alvotech Receives FDA Approval for New SIMLANDI® Manufacturing Process That More Than Doubles Output Per Batch

Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech’s biosimilars portfolio REYKJAVIK, Iceland and LONDON, Oct. 20, 2026 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a new manufacturing process for SIMLANDI® (adalimumab-ryvk), Alvotech’s biosimilar to Humira® (adalimumab). The FDA approval allows Alvotech to introduce Process 2.0 for the manufacture of adalimumab drug substance in its DSM2 manufacturing suite in Reykjavik, Iceland. The new process more than doubles drug substance output per batch without changing the upstream manufacturing scale. The improvement...

Continue reading

Form 8.3 – [ADVANCED MEDICAL SOLUTIONS GROUP PLC – 19 10 2026] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ADVANCED MEDICAL SOLUTIONS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Water shortages will threaten growth within five years, say over half of European industrial leaders

Water shortages will threaten growth within five years, say over half of European industrial leadersWater shortages will threaten growth within five years, say over half of European industrial leadersWater stress is already hitting operating costs, supply chains and infrastructure across European industry Water shortages now rank as high as cyber-attacks and supply chain disruption for industrial business continuity Nearly 60% of leaders admit to not installing the technology they know could cut water riskPARIS, Oct. 20, 2026 (GLOBE NEWSWIRE) — Schneider Electric, a global energy technology leader, today released The Water Crunch Report, new research revealing that water is now one of the biggest risks to industrial business continuity across the UK and Europe, ranking as highly as cyber-attacks and supply chain disruption....

Continue reading

Quadient Named a Leader in the 2026 IDC MarketScape for Worldwide Intelligent Customer Communication Management

Paris Quadient (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, announced today that it has been named a Leader in the IDC MarketScape: Worldwide Intelligent Customer Communication Management 2026 Vendor Assessment (IDC #US54131626, September 2026). Quadient believes its recognition as a Leader reflects the breadth, depth and proven capabilities of Quadient’s customer communications management solution, Quadient Inspire. According to Amy Machado, research director at IDC: “As customer communications management evolves into AI-powered customer experience orchestration, Quadient differentiates through its innovation, deployment flexibility, and commitment to helping organizations deliver meaningful customer interactions. By combining AI-driven customer communications, customer journey...

Continue reading

VINCI wins a contract for a data center in the Iberian Peninsula

Nanterre, 20 October 2026 VINCI wins a contract for a data center in the Iberian PeninsulaConstruction of a cooling plant for a major data center campus A €165 million contract value Strengthening the Group’s position in the digital infrastructure portfolioCobra IS has been awarded a new contract for the construction of a cooling plant for a major data center campus in the Iberian Peninsula. The project, a €165 million contract value, includes the delivery of mechanical, electrical, and plumbing (MEP) installations for 126 dry coolers. They will cool the equivalent of 200 MW of computing capacity and play a critical role in keeping the campus operating reliably. Cobra IS is currently in the process of bidding for further phases of this data center campus worth several billion euros in total. This new contract further reinforces VINCI’s...

Continue reading

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today announced that new biomarker data from the Phase 2 ACUITY trial of Privosegtor will be featured in a late-breaking session at the 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto 2026), on October 21-23, 2026, in Toronto, Canada. The presentation will unveil new analyses evaluating circulating neuroaxonal and neuroinflammatory biomarkers, specifically plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), in patients with acute optic neuritis...

Continue reading

Consensus estimates ahead of Q3 2026

Alm. Brand Group hereby publish consensus estimates prior to the announcement of the Q3 results. Consensus estimates are also available via: almbrand.dk Conference Call Alm. Brand Group will report its Q3 2026 results on 28 October at around 07:30 CET and host a conference call with management at 11:00 CET on the day of release. Dial in for analysts and investors (Conference ID: 463 676 395): Denmark: +45 80 83 03 77 UK: +44 117 389 0104 USA: +1 585 542 9983 Contact Please direct any questions regarding this announcement to: Investors and equity analysts:                          Mads Thinggaard – Head of Investor Relations & ESG – mobile no. +45 2025 5469                                                                                                          Press:                                                                                           ...

Continue reading

ARGAN: Availability of the Merger Auditor’s Report

Press release – Neuilly-sur-Seine, Tuesday, October 19, 2026 – 8.00 am Availability of the Merger Auditor’s Report ARGAN hereby informs its shareholders that the report prepared by Mr. Olivier Péronnet, Partner at Finexsi – Expert & Conseil Financier, acting as merger auditor appointed by order of the President of the Nanterre Commercial Activities Court dated July 28, 2026, is available to them as of today. In his report, prepared in connection with the proposed cross-border merger with Warehouses De Pauw NV (“WDP”), a company incorporated under Belgian law, the merger auditor concludes as follows:“The exchange ratio of 3 WDP shares for 1 ARGAN share, following the exceptional distribution of €11 per share, as agreed by the parties, is fair; and The withdrawal price of €71.10 agreed upon by the parties, corresponding to €60.10...

Continue reading

Ambrose Healthcare Acquires AM-Pharma for Up to €161 Million, Expanding its Rare Disease Pipeline and Gaining a European Base

, Oct. 20, 2026 (GLOBE NEWSWIRE) — CAMBRIDGE, UK & UTRECHT, THE NETHERLANDS – October 20, 2026 – Ambrose Healthcare, a rare disease specialist, has acquired 100% of the shares of AM-Pharma. Under the terms of the agreement, AM-Pharma’s shareholders are entitled to receive up to €161 million comprising an upfront payment and milestone payments contingent on the commercialisation of AM-Pharma’s Phase 2-ready treatment for hypophosphatasia (HPP), and royalties on future sales. Other financial terms are not disclosed. In addition to adding ilofotase alfa for HPP to Ambrose’s clinical pipeline, it gives the company its first base in Europe – in Utrecht, The Netherlands. HPP is a rare, inherited chronic disease caused by low alkaline phosphatase activity, leading to bone fractures, tooth loss, muscle weakness, fatigue...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.